Alliance Global Partners lowered the firm’s price target on Intensity Therapeutics (INTS) to $3.50 from $8.50 and keeps a Buy rating on the shares. The price target reduction reflects the trial delay for INT230-6 for soft tissue sarcoma, the analyst tells investors in a research note. The trial is being paused until further notice due to funding constraints, and the firm believes it will take a major funding event to get it back on track.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS:
- Intensity Therapeutics Faces Nasdaq Non-Compliance Notice
- Intensity Therapeutics downgraded to Hold from Buy at Brookline
- Intensity Therapeutics Reports Q1 2025 Financial Results
- Intensity Therapeutics reports Q1 EPS (22c) vs. (34c) last year
- Intensity and SAKK announce EMA authorization to begin with INVINCIBLE-4